CA3048040A1 - Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases - Google Patents

Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases Download PDF

Info

Publication number
CA3048040A1
CA3048040A1 CA3048040A CA3048040A CA3048040A1 CA 3048040 A1 CA3048040 A1 CA 3048040A1 CA 3048040 A CA3048040 A CA 3048040A CA 3048040 A CA3048040 A CA 3048040A CA 3048040 A1 CA3048040 A1 CA 3048040A1
Authority
CA
Canada
Prior art keywords
sox18
protein
compound
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3048040A
Other languages
English (en)
French (fr)
Inventor
Mathias FRANCOIS
Johannes Zuegg
Robert John Capon
Frank Roger Fontaine
Avril Alexis Barbara Robertson
Matthew Allister Cooper
Angela Aguslyarti Salim
Sreeman Kumar Mamidyala
Jeroen Overman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905362A external-priority patent/AU2016905362A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CA3048040A1 publication Critical patent/CA3048040A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/331—Polycyclic acids with all carboxyl groups bound to non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3048040A 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases Pending CA3048040A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905362A AU2016905362A0 (en) 2016-12-23 Compounds and use thereof in methods of treatment
AU2016905362 2016-12-23
PCT/AU2017/051439 WO2018112545A1 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases

Publications (1)

Publication Number Publication Date
CA3048040A1 true CA3048040A1 (en) 2018-06-28

Family

ID=62624141

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3048040A Pending CA3048040A1 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases

Country Status (8)

Country Link
US (3) US11434190B2 (enExample)
EP (1) EP3558293A4 (enExample)
JP (2) JP7579057B2 (enExample)
KR (1) KR102572077B1 (enExample)
CN (1) CN110536685A (enExample)
AU (1) AU2017383102B2 (enExample)
CA (1) CA3048040A1 (enExample)
WO (1) WO2018112545A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112545A1 (en) 2016-12-23 2018-06-28 The University Of Queensland Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
CN110143941B (zh) * 2019-06-04 2021-05-25 北京四环制药有限公司 一种巴罗萨韦玛波酯中间体的合成方法
AU2020464868A1 (en) * 2020-08-26 2023-04-13 Gertrude Biomedical Pty Ltd Antiviral SOX inhibitors
CN118834915A (zh) * 2024-08-15 2024-10-25 扬州大学 一种在羊毛乳头细胞中稳定过表达的sox18慢病毒重组标签载体的构建及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314725A1 (en) 1987-05-19 1989-05-10 FISONS plc 2-(3,4-dihydroxyphenyl)ethylamines, their preparation and use as pharmaceutical
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
DE10015525A1 (de) 2000-03-30 2001-10-11 Deutsches Krebsforsch Synthetische Derivate von Lunularsäure, Arzneimittel enthaltend diese Verbindung, Verfahren zur Herstellung der Lunularsäurederivate sowie deren Verwendung
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
ITRM20030355A1 (it) * 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
CN101062043B (zh) * 2006-04-30 2011-06-08 浙江天皇药业有限公司 3,4,5,4'-四甲氧基二苯乙烷-3’-o-磷酸二钠在抗肿瘤及其转移药物的应用
CN101235003B (zh) * 2007-02-01 2010-09-15 浙江赛尔生物医学研究有限公司 3,4,5,4'-四甲氧基-α,β-二苯乙烷-3'-O-硫酸酯钠盐及其应用
EA201100615A1 (ru) * 2008-10-13 2011-12-30 Новартис Аг Производные салициловой кислоты в качестве ингибиторов активности фарнезилпирофосфатсинтазы
CN103037690B (zh) 2010-03-24 2016-04-27 俄亥俄州立大学 用于葡萄糖转运抑制的组合物和方法
CN102050759A (zh) * 2010-12-09 2011-05-11 江苏天晟药业有限公司 白藜芦醇酰胺类衍生物及其制备方法
CA2941010A1 (en) * 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
EP3060237B1 (en) * 2013-10-25 2021-08-18 Wayne State University Modified reprogramming protein for use in treating a cancer
WO2018112545A1 (en) * 2016-12-23 2018-06-28 The University Of Queensland Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
AU2020464868A1 (en) * 2020-08-26 2023-04-13 Gertrude Biomedical Pty Ltd Antiviral SOX inhibitors

Also Published As

Publication number Publication date
EP3558293A1 (en) 2019-10-30
CN110536685A (zh) 2019-12-03
AU2017383102B2 (en) 2023-05-11
JP7579057B2 (ja) 2024-11-07
KR20190105018A (ko) 2019-09-11
JP2023011613A (ja) 2023-01-24
JP2020506884A (ja) 2020-03-05
EP3558293A4 (en) 2020-10-28
AU2017383102A1 (en) 2019-08-01
US12410116B2 (en) 2025-09-09
KR102572077B1 (ko) 2023-08-29
US11434190B2 (en) 2022-09-06
WO2018112545A1 (en) 2018-06-28
US20230100768A1 (en) 2023-03-30
US20190337880A1 (en) 2019-11-07
US20240002326A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US12410116B2 (en) Compounds and use thereof in methods of treatment
Holden et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling
JP6592071B2 (ja) ヒトｅｚｈ２の阻害剤およびその使用方法
Bouché et al. Benzoisoquinolinediones as potent and selective inhibitors of BRPF2 and TAF1/TAF1L bromodomains
Wang et al. Development of potent type I protein arginine methyltransferase (PRMT) inhibitors of leukemia cell proliferation
An et al. A-Raf: A new star of the family of raf kinases
HUE027534T2 (en) Notch pathway inhibitory compound
AU2016356884A1 (en) Novel compounds as inhibitors of dna methyltransferases
Gradl et al. Discovery of the SMYD3 inhibitor BAY-6035 using thermal shift assay (TSA)-based high-throughput screening
Chang et al. Discovery of novel PROTAC degraders of p300/CBP as potential therapeutics for hepatocellular carcinoma
Palombo et al. The promoter-associated noncoding RNA PNCCCND1_B assembles a protein–RNA complex to regulate cyclin D1 transcription in Ewing sarcoma
Shukla et al. Mutations of RNA splicing factors in hematological malignancies
Miller et al. Diarylthiophenes as inhibitors of the pore-forming protein perforin
Yap et al. Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein–protein and protein–DNA interactions
Du et al. Discovery and synthesis of a naturally derived protein kinase inhibitor that selectively inhibits distinct classes of serine/threonine kinases
Sun et al. Structure-guided discovery of potent and selective CLK2 inhibitors for the treatment of knee osteoarthritis
Shrestha et al. Cyclin‐Dependent Kinase 11: Cellular Functions and Potential Therapeutic Applications
WO2023190967A1 (ja) イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー
Cursaro et al. Targeting N‐Methyl‐lysine Histone Demethylase KDM4 in Cancer: Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery
Liu et al. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer
Uguen et al. Tudor-Containing Methyl-Lysine and Methyl-Arginine Reader Proteins: Disease Implications and Chemical Tool Development
Duan et al. Biology of Chondrosarcoma
EP4291195A1 (en) Small molecule inhibitors of pbrm1-bd2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221215

EEER Examination request

Effective date: 20221215